Table 4.
Studies that investigated central nervous system infiltration among patients with diffuse large B-cell lymphoma
| Author | n | Age (years) | Stage III-IV (%) | IPI intermediate/ high (%) | CNS infiltration (%) | R |
| Feugier et al.(4) | 399 | 47% > 70 | 79 | 60 | 5 | no |
| Arkenou et al.(5) | 259 | 62 (mean) | 42 | 36 | 1.1 | NR |
| Shimazu et al.(3) | 399 | 71 (mean) | 56 | 49 | 10.4 | yes |
| Boehme et al.(10) | 1.222 | 36% > 70 | 50.5 | 41.7 | 4.8 | yes |
| Villa et al.(8) | 435 | 65 (mean) | 70 | 61 | 7.1 | yes |
| Yamamoto et al.(9) | 375 | 66.4% > 60 | 39.2 | 35.4 | 3.5 | no |
| Tai et al.(7) | 499 | 60% > 60 | 44.0 | 26.0 | CHOP: 5.1 RCHOP: 6.0 | no |
| Chihara et al.(11) | 386 | 54% > 60 | 41 | 31 | 7.9 | no |
| Current study (2011) | 133 | 52.4 (mean) | 54.1 | 36.7 | 6.7 | NR |
CNS: Central nervous system; IPI = International Prognostic Index; R = rituximab as protective factor; NR = not reported